Zacks Research Equities Analysts Cut Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH)

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at Zacks Research reduced their FY2024 earnings per share estimates for Theravance Biopharma in a report released on Monday, April 15th. Zacks Research analyst K. Shah now anticipates that the biopharmaceutical company will post earnings of ($0.89) per share for the year, down from their prior forecast of ($0.87). The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.84) per share. Zacks Research also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at ($0.33) EPS and FY2026 earnings at $0.84 EPS.

Several other equities research analysts also recently issued reports on the company. BTIG Research began coverage on Theravance Biopharma in a report on Friday, April 12th. They issued a “buy” rating and a $21.00 price objective on the stock. Evercore ISI downgraded Theravance Biopharma from an “outperform” rating to an “inline” rating in a report on Monday, January 8th.

Theravance Biopharma Trading Down 3.4 %

TBPH stock opened at $9.20 on Wednesday. The company has a market capitalization of $446.75 million, a PE ratio of -9.48 and a beta of 0.36. Theravance Biopharma has a 12-month low of $8.21 and a 12-month high of $11.98. The business’s fifty day moving average price is $9.00 and its 200 day moving average price is $9.66.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The firm had revenue of $17.57 million during the quarter, compared to analysts’ expectations of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. Bank of America Corp DE boosted its position in shares of Theravance Biopharma by 102.4% during the 1st quarter. Bank of America Corp DE now owns 1,775,966 shares of the biopharmaceutical company’s stock worth $19,269,000 after acquiring an additional 898,691 shares in the last quarter. Two Sigma Advisers LP acquired a new position in shares of Theravance Biopharma during the 3rd quarter worth about $7,064,000. Two Sigma Investments LP acquired a new position in shares of Theravance Biopharma during the 3rd quarter worth about $6,620,000. Vanguard Group Inc. boosted its position in shares of Theravance Biopharma by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after acquiring an additional 648,124 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Theravance Biopharma by 184.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 976,373 shares of the biopharmaceutical company’s stock worth $9,335,000 after acquiring an additional 632,582 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.